Whar about Astragalus

Armando Jose

Senior Member
My Regimen
Reaction score
975
It seem interesting
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0092984

Apoptosis with premature termination of hair follicle growth induces several types of hair loss and is one of the crucial factors of hair loss. Astragaloside IV, which is a major component of Astragalus membranaceus, is a cycloartane triterpene saponin. Although an anti-apoptotic effect of Astragaloside IV has been reported, its effects against hair loss have not been investigated. To explore the underlying mechanisms of Astragaloside IV on apoptotic signaling in hair follicle, the dorsal skin of depilated C57BL/6 mice was topically treated with 1 and 100 μM Astragaloside IV for 14 days. In Astragaloside IV-treated group, TUNEL-positive cells were reduced. We found that Astragaloside IV blocked the procaspase-8, resulting in the inhibition of caspase-3 and procaspase-9 activities. The changes were accompanied with down-regulation of Bax and p53, and up-regulation of Bcl-2 and Bcl-[SUB]xL[/SUB] by Astragaloside IV treatment. In addition, activation of NF-κB and phosphorylation of IκB-α were inhibited, along with decreases in three MAPKs: ERK, SAPK/JNK and p38 by Astragaloside IV. The expressions of KGF, p21, TNF-α and IL-1β, which are keratinocyte terminal differentiation markers associated with catagen, were modulated by treatment with Astragaloside IV. These results demonstrated that Astragaloside IV is concerned with blocking the Fas/Fas L-mediated apoptotic pathway, which would be an alternative therapy for hair loss.
 

waynakyo

Experienced Member
Reaction score
464
was going to post this, seen another claim somewhere else can't remember.. logevity people use this supplement, it is worth looking into. The poster above said he halted his hair loss and disappeared from the forum after.
 

Armando Jose

Senior Member
My Regimen
Reaction score
975
The extract come from the root, ....
more information about it
Astragaloside benefit in medicine
March 11 2014
J Ethnopharmacol. 2013 Oct 25. Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF-кB signaling pathway in isoproterenol-induced myocardial hypertrophy.
Heart Tissue
Biol Pharm Bull. 2013. Effects of Astragaloside IV on Action Potentials and Ionic Currents in Guinea-Pig Ventricular Myocytes. Department of Pharmaceutical Toxicology, School of Pharmaceutical Science, China Medical University. Astragaloside IV (AS-IV) is one of the main active constituents of Astragalus membranaceus, which has various actions on the cardiovascular system. However, its electrophysiological mechanisms are not clear. In the present study, we investigated the effects of AS-IV on action potentials and membrane currents using the whole-cell patch clamp technique in isolated guinea-pig ventricular myocytes. AS-IV prolonged the action potential duration (APD) at all three tested concentrations. Astragaloside IV prolonged APD of guinea-pig ventricular myocytes, which might be explained by its inhibition of IK. AS-IV also influences Ca(2+) signaling through suppressing ICaL.
Astragaloside IV regulates expression of ATP-sensitive potassium channel subunits after ischemia-reperfusion in rat ventricular cardiomyocytes.
J Tradit Chin Med. 2011. Han XH, Liu P, Zhang YY, Zhang N, Chen FR, Cai JF. Scientific Research Center, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Astragaloside IV (AsIV) is the major effective component extracted from the Chinese herb Astragalus membranaceus, which has been widely used to treat cardiovascular disease. Recent studies have shown that AsIV can potentially protect the heart from myocardial ischemic injury, but the mechanisms of action are unknown. ATP-sensitive potassium (KATP) channels are activated during ischemia and exert a compensatory protective effect on cardiomyocytes. We therefore examined the effects of AsIV on KATP channel currents and channel expression in isolated rat ventricular cardiomyocytes after ischemia-reperfusion injury. Forty Wistar rats were divided into five groups: control group, ischemia-reperfusion (IP) group, IP + glibenclamide group, IP + pinacidil group and IP + AsIV group. The ischemia-reperfusion injury model was established in enzymatically isolated ventricular cardiomyocytes by perfusion with calcium-free Tyrode solution for 10 min, arrest for 30 min, and reperfusion for 45 min. The different drugs were applied for 10-15 min, and the KATP channel current (I(KATP)) was recorded with voltage-clamp mode by whole-cell patch-clamp technique. Protein and mRNA expression of the KATP channel subunits Kir6.1, Kir6.2, SUR2A and SUR2B was quantified using western blotting and real-time PCR. The KATP current in IP group was significantly greater than that in control group. Glibenclamide (10 micromol/L) blocked KATP currents, whereas both AsIV (1 mg/L) and the known channel opener pinacidil (50 micromol/L) significantly increased I(KATP). Consistent with this, AsIV significantly up-regulated protein and mRNA expression of Kir6.1, Kir6.2, SUR2A, SUR2B. The protective effects of AsIV in ischemia-reperfusion injury may be related to the up-regulation of several KATP channel subunits and facilitation of KATP currents.
Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products.
J Agric Food Chem. 2009; Motomura K, Kiyota N, Tsurushima K, Takeya M, Nohara T. Department of Natural Medicine, Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
Because advanced glycation end product (AGE) inhibitors such as pyridoxamine significantly inhibit the development of retinopathy and neuropathy in the streptozotocin-induced diabetic rat, treatment with AGE inhibitors is believed to be a potential strategy for the prevention of lifestyle-related diseases such as diabetic complications. A crude extract of Astragali Radix (AR; roots of Astragalus membranaceus ) inhibits the formation of N(epsilon)-(carboxymethyl)lysine (CML) and pentosidine during the incubation of bovine serum albumin with ribose. In the present study, compounds were isolated from AR that prevented CML and pentosidine formation. Astragalosides significantly inhibited the formation of both CML and pentosidine, and astragaloside V had the strongest inhibitory effect among all if the isolated compounds. These data suggest that AR and astragalosides may be a potentially useful strategy for the prevention of clinical diabetic complications by inhibiting advanced glycation end products.
 

waynakyo

Experienced Member
Reaction score
464
Good question, the forum has a life of its own no one predicts where it might go. You might drop the cure on them and they might notice it because they are busy discussing conspiracy theories..

I do think excellent treatments get ignored. Take RU for example. ElDuta was talking about it since 2008 at least, no one else heard him. 6 years later RU is now mainstream and no one will challenge it.

Similarly, people have ignored the PGD2 story, despite the science AND the positive evidence on this forum. I had a great response to OC, and discussed it on this forum, no one cares. I even started a thread asking who did NOT have a positive response to OC and no one responded...

I also found out that Elduta is using neogenic with success, it turns out that some people are getting something, not a lot, but something...
 

benjt

Experienced Member
Reaction score
100
These results demonstrated that Astragaloside IV is concerned with blocking the Fas/Fas L-mediated apoptotic pathway
The question is: Is that even relevant for Androgenetic Alopecia? As far as I know, Androgenetic Alopecia is a downstream effect of Wnt/b-catenin signalling pathway impairment. I don't know if the Fas L pathway is in any way related to the Wnt/b-catenin pathway but if it isn't, then this is probably not a viable approach.
 

Python

Established Member
Reaction score
45
Let's just get a couple of labrats on the forum on this and be done with it. Also, benjt, there is plenty other people with alopecia that lose hair and may benefit.
 

benjt

Experienced Member
Reaction score
100
Also, benjt, there is plenty other people with alopecia that lose hair and may benefit.
That may be, but it doesnt help 90% of the forum members (namely the ones suffering from Androgenetic Alopecia/male pattern baldness) if the Fas ligand pathway is not connected to the Wnt/b-catenin pathway.
 
K

karankaran

Guest
How about the TNF-alpha , DKK1 pathway? Can this help with that? I think so.
 

Jacob

Senior Member
Reaction score
44
Why is no one even remotely interested in this?

I'm remotely interested :cool: It has been discussed before I know...in other forums as well. I recall posting some (skin I think) topicals that contained it.
 

benjt

Experienced Member
Reaction score
100
How about the TNF-alpha , DKK1 pathway? Can this help with that? I think so.
Firstly, TNF-alpha and DKK-1 are not pathways in the sense of Wnt, but specific signalling molecules. Secondly, why do you think that the Fas pathway can help here? The Fas pathway is indeed involved in TNF regulation, but that is waaaaay more downstream from other relevant effects like DKK-1 upregulation which - as far as I can tell - the Fas pathway has no connection to at all. In fact, DKK-1 is even upstream of Wnt's workings.
 
K

karankaran

Guest
Firstly, TNF-alpha and DKK-1 are not pathways in the sense of Wnt, but specific signalling molecules. Secondly, why do you think that the Fas pathway can help here? The Fas pathway is indeed involved in TNF regulation, but that is waaaaay more downstream from other relevant effects like DKK-1 upregulation which - as far as I can tell - the Fas pathway has no connection to at all. In fact, DKK-1 is even upstream of Wnt's workings.

No, what i meant was i read in some science literature that a way target DKK1 is to inhibit TNF-alpha. Since DKK1 is implicated in male pattern baldness and i guess reducing it helps activate Wnt pathway? and this compound mentioned here has an effect on TNF-alpha. Hence, i asked , not in relation to Fas pathway.
 
Top